These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 8145772

  • 1. Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity.
    Costantino A, Milazzo G, Giorgino F, Russo P, Goldfine ID, Vigneri R, Belfiore A.
    Mol Endocrinol; 1993 Dec; 7(12):1667-76. PubMed ID: 8145772
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity.
    Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, Maddux B, Goldfine ID, Vigneri R.
    Mol Endocrinol; 1996 Nov; 10(11):1318-26. PubMed ID: 8923458
    [Abstract] [Full Text] [Related]

  • 3. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E.
    Cancer Res; 2001 Sep 15; 61(18):6747-54. PubMed ID: 11559546
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-1 blocks insulin and insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity.
    Costantino A, Vinci C, Mineo R, Frasca F, Pandini G, Milazzo G, Vigneri R, Belfiore A.
    Endocrinology; 1996 Oct 15; 137(10):4100-7. PubMed ID: 8828463
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
    Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK.
    Cancer Res; 1992 Jul 01; 52(13):3636-41. PubMed ID: 1617636
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor.
    Elbaz N, Bedecs K, Masson M, Sutren M, Strosberg AD, Nahmias C.
    Mol Endocrinol; 2000 Jun 01; 14(6):795-804. PubMed ID: 10847582
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines.
    Jackson JG, Zhang X, Yoneda T, Yee D.
    Oncogene; 2001 Nov 01; 20(50):7318-25. PubMed ID: 11704861
    [Abstract] [Full Text] [Related]

  • 11. Characterization of insulin and insulin-like growth factor-I actions in the bovine luteal cell: regulation of receptor tyrosine kinase activity, phosphatidylinositol-3-kinase, and deoxyribonucleic acid synthesis.
    Chakravorty A, Joslyn MI, Davis JS.
    Endocrinology; 1993 Sep 01; 133(3):1331-40. PubMed ID: 8396016
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I.
    Auclair M, Vigouroux C, Desbois-Mouthon C, Deibener J, Kaminski P, Lascols O, Cherqui G, Capeau J, Caron M.
    J Clin Endocrinol Metab; 1999 Sep 01; 84(9):3197-206. PubMed ID: 10487687
    [Abstract] [Full Text] [Related]

  • 14. Effect of phosphotyrosyl-IRS-1 level and insulin receptor tyrosine kinase activity on insulin-stimulated phosphatidylinositol 3, MAP, and S6 kinase activities.
    Wilden PA, Broadway DE.
    J Cell Physiol; 1995 Apr 01; 163(1):9-18. PubMed ID: 7896903
    [Abstract] [Full Text] [Related]

  • 15. The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin.
    Guvakova MA, Surmacz E.
    Exp Cell Res; 1999 Aug 25; 251(1):244-55. PubMed ID: 10438590
    [Abstract] [Full Text] [Related]

  • 16. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism.
    Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R, Belfiore A.
    Oncogene; 1999 Apr 15; 18(15):2471-9. PubMed ID: 10229198
    [Abstract] [Full Text] [Related]

  • 17. Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.
    Bentel JM, Lebwohl DE, Cullen KJ, Rubin MS, Rosen N, Mendelsohn J, Miller WH.
    J Cell Physiol; 1995 Oct 15; 165(1):212-21. PubMed ID: 7559803
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.
    Arteaga CL, Osborne CK.
    Cancer Res; 1989 Nov 15; 49(22):6237-41. PubMed ID: 2553250
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.